Ayala Pharmaceuticals Inc (ADXS)

[fbg0316]

Thanks James, this is encouraging looking at the separate Merck monotherapy next to our monotherapy data and the combo data. While we can't directly compare the Merck monotherapy data to our recent monotherapy data because of different populations and pre-treatment regimes, generally speaking it would appear that our monotherapy data is within the ballpark of Merk's monotherapy data, but combined the two therapies represent a meaningful improvement. Hovacre may want to weight in from a scientific background.

Merck PD1 Prostate Monotherapy = 19% PSA declines
ADXS PSA Prostate Monotherapy = 15.4% PSA declines
Merk & ADXS Combined Therapies = 40.5% PSA declines